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A B S T R A C T
Mitochondrial diseases, caused by mutations in either the nuclear or mitochondrial genomes (mtDNA), are the
most common form of inherited neurometabolic disorders. They are remarkably heterogeneous, both in their
clinical presentation and genetic etiology, presenting challenges for diagnosis, clinical management and eluci-
dation of molecular mechanism. The multifaceted nature of these diseases, compounded by the unique char-
acteristics of mitochondrial genetics, cement their space in the field of complex disease. In this review we
examine the m.3243A>G variant, one of the most prevalent mitochondrial DNA mutations, using it as an
exemplar to demonstrate the challenges presented by these complex disorders. Disease caused by m.3243A>G
is one of the most phenotypically diverse of all mitochondrial diseases; we outline known causes of this het-
erogeneity including mtDNA heteroplasmy, mtDNA copy number and nuclear genetic factors. We consider the
impact that this has in the clinic, discussing the personalized management of common manifestations attributed
to this pathogenic mtDNA variant, including hearing impairment, diabetes mellitus, myopathy, cardiac disease,
stroke-like episodes and gastrointestinal disturbances. Future research into this complex disorder must account
for this heterogeneity, benefitting from the use of large patient cohorts to build upon current clinical expertise.
Through multi-disciplinary collaboration, the complexities of this mitochondrial disease can be addressed with
the variety of diagnostic, prognostic, and treatment approaches that are moulded to best fit the needs of each
individual patient.
1. Introduction
Mitochondrial diseases are the most common form of inherited
neuro-metabolic disorders, with pathogenic DNA variants in both nu-
clear and mitochondrial genomes affecting an estimated 1 in 4300 in-
dividuals [1,2]. They are often challenging to diagnose because of their
phenotypic heterogeneity, frequently affecting multiple systems. How-
ever, the high-throughput gene-based diagnostic technology available
in the last decade, along with detailed phenotyping by highly-specia-
lized clinical services and longitudinal natural history studies have
accelerated the steep rise in identification of pathogenic mutations
[2–4]. One of the first and most prevalent pathogenic mitochondrial
DNA (mtDNA) single nucleotide variants to be identified, the
m.3243>G MT-TL1 gene mutation, remains a significant challenge,
not only in elucidating the precise molecular mechanisms underlying
pathogenicity, but also in linking these to the wide spectrum of clinical
phenotypes caused by the pathogenic variant.
In this review, we will consider m.3243A>G-related mitochondrial
disease as a complex disorder, outlining our current knowledge of the
factors that are believed to lead to its variable phenotypic expression
(Fig. 1). We will then examine the challenges that this imposes on pa-
tients, detailing how we can tailor clinical practice, from initial as-
sessment through to molecular diagnosis, detailed clinical assessment
and management of individual phenotypes. Finally, we will consider
how the complexity of this fascinating mutation directs our clinical and
laboratory research and how they, in turn, have the potential to en-
hance the personalized clinical experience of patients.
2. Mitochondria and the mitochondrial genome
Mitochondria are present in all nucleated cells and are the principal
generators of adenosine triphosphate (ATP) via oxidative phosphor-
ylation (OXPHOS). A dynamic organelle, the mitochondrion is involved
in a variety of cellular processes including differentiation, cell growth,
apoptosis, nitrogen metabolism, fatty acid metabolism [4–8]. Mi-
tochondria are responsive to the intra-cellular environment, and have
the ability to remodel in response to changes in respiratory states,
through mitochondrial fission and fusion [9].
Mitochondria are unique as they are under the dual control of their
own mitochondrial genome (mtDNA) and that of the nuclear genome
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[10,11]. The human mitochondrial genome is a compact 16,569 base
pair, double-stranded, circular molecule that is present in multiple co-
pies per cell and encodes 13 genes, two ribosomal RNA molecules and
22 transfer RNA (tRNA) molecules [12–14]. The multicopy nature of
mtDNA can give rise to heteroplasmy - the coexistence of more than one
type of mtDNA within the same cell [2]. For heteroplasmic mutations,
an individual would typically not show a manifestation of disease until
a ‘threshold’ level of mutation has been reached [15]. Mitochondrial
disease can also result from homoplasmic mutations, where the muta-
tion is present in every copy of mtDNA [16,17]; alterations in cellular
mtDNA copy number are also linked with disease [18,19]. The in-
heritance of mtDNA is not controlled by the same rules as the in-
heritance of nuclear chromosomal genes; mitochondria and mtDNA are
maternally inherited [20]. Although very rare instances of bi-parental
inheritance have been described [21,22], alternative explanations [23]
for these results have not been excluded, therefore maternal inheritance
of mtDNA remains the recognized mechanism of inheritance in humans.
3. The m.3243A>G variant
The A to G transition at position 3243 in the mitochondrial genome
within MT-TL1 (mitochondrially- encoded tRNALeu[UUR]) was initially
identified as pathogenic by Goto and colleagues in 1990, within a pa-
tient cohort diagnosed with mitochondrial encephalopathy, lactic
acidosis, and stroke-like episodes – also known as MELAS syndrome
[24]. Later the same year this finding was corroborated by Kobayashi
et al. [25]. Subsequent studies have shown that although m.3243A>G
is the most common cause of MELAS, not all individuals diagnosed with
MELAS harbour this variant, and the vast majority of individuals who
carry m.3243A>G do not have a clinical diagnosis of MELAS. Popu-
lation studies have estimated that 140-250 individuals per 100,000
carry the m.3243A>G variant [26,27], however the point prevalence
for adult clinical disease is 40-70 times lower than this at 3.5 in 100,000
[2].This implies that a large number of m.3243A>G carriers are
clinically asymptomatic or have milder symptoms not recognized as
mitochondrial disease.
There have been several attempts to elucidate the pathogenic me-
chanism of action of the m.3243A>G variant; hypotheses have in-
cluded impairment of mt-rRNA transcription termination [28,29], a
decrease in the steady state levels of aminoacylated mt-tRNA(Leu[UUR])
[30–32], or amino acid misincorporation [31,33,34]. There is a broad
consensus that m.3243A>G causes defects in mitochondrial protein
synthesis and respiratory chain activity [34,35], but a full under-
standing has yet to be established. The use of transmitochondrial cybrid
cells to investigate proposed mechanisms of action of the m.3243A>G
variant is one reason the question of pathogenesis remains, as being
highly aneuploid and genetically unstable may mean that direct in vitro
- in vivo comparisons are unreliable [34].
Fig. 1. Understanding m.3243A>G as a complex genetic disease. Cartoon showing how the phenotypic expression of m.3243A>G MT-TL1 can be influenced by
several factors. (Clockwise from left) The clinical phenotypes associated with this specific mtDNA variant are numerous, affecting multiple organ systems, but
commonly involving the brain and CNS, auditory system, endocrine system and skeletal muscle. Human cells typically contain many mitochondria which have
multiple copies of their own circular DNA. In the case of patients with the m.3243A>G variant, mtDNA is present in two forms - mutant mtDNA (shown in red) and
wild-type mtDNA (shown in green). Also shown is the position of the MT-TL1 gene in the circular mitochondrial genome, and the position within the variable DHU
loop of mt-tRNALeu(UUR) where the A to G substitution occurs. The phenotypic expression of this point mutation can be influenced by numerous factors as shown,
including m.3243A>G mutant load (i.e. mtDNA heteroplasmy levels), the segregation of mutant mtDNAs between different organs in the body, the genetic
bottleneck which governs the transmission of the m.3243A>G variant, mtDNA copy number and other factors including nuclear genetic determinants and en-
vironmental factors.
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4. Phenotypic variability
The clinical presentation of m.3243A>G-related disease poses a
major diagnostic challenge for clinicians; disease can occur at almost
any stage of life, and can affect multiple organ systems [36]. In addi-
tion, the burden of disease and its progression is highly variable be-
tween individuals, resulting in a broad phenotypic spectrum of disease
[37]. MELAS affects approximately 15% of all m.3243A>G patients
[38]; of those patients diagnosed with MELAS, 80% harbor the
m.3243A>G variant [39,40]. Other syndromes linked to the
m.3243A>G variant include maternally inherited diabetes and deaf-
ness (MIDD) and progressive external ophthalmoplegia (PEO) [11,41].
Epidemiological studies have repeatedly shown that presentation of
m.3243A>G-related disease is more frequently associated with MIDD
than with MELAS [38,42–45].
A concern from epidemiological and clinical perspectives is that
medical problems occurring in isolation may not be recognized as
having a mitochondrial etiology and the diagnosis will be made only
when a ‘syndromic’ combination of organ involvement occurs. Several
of the classical syndromes related to m.3243A>G can occur in com-
bination within a single patient and many patients demonstrate a pa-
noply of clinical features, including myopathy, cardiac disease, short
stature, kidney involvement and gastrointestinal disturbances, not
consistent with any classic syndromes [38,42–47]. Another challenge is
that mitochondrial disease secondary to other mitochondrial DNA or
nuclear genome pathogenic mutations can present similarly to those of
m.3243A>G mutation. Some of the clinical features associated with
this mutation might also be evident in patients carrying other mtDNA
point mutations [3,36,48].
5. Heteroplasmy
Variation in mtDNA heteroplasmy levels, the critical ratio of mutant
to wild-type mtDNA molecules within the same cell, adds a degree of
complexity to our understanding of m.3243A>G-related disease.
Individuals who harbor the m.3243A>G variant can do so at very
different levels between different cells, tissues and each other. The
classic hypothesis describes a situation where biochemical deficiency is
only exhibited above a tissue and mutation specific threshold of het-
eroplasmy. The rationale being that there is considerable redundancy in
the requirement for wild type mtDNA for synthesis of mitochondrial
components necessary for OXPHOS. Work in cybrid cell lines supports
this hypothesis; increases in heteroplasmy levels result in abrupt tran-
scriptional reprogramming, the mechanism of which is likely related to
epigenetic changes in nuclear DNA [49,50]. However, for reasons
outlined above, studies in cybrid cells must be interpreted with caution;
unfortunately, demonstrating similar responses in vivo has proved more
challenging.
Considering the threshold hypothesis, it would seem likely that the
level of heteroplasmy harbored by an individual would be correlated
with disease burden; this relationship is certainly not clear and is fur-
ther complicated by the fact that heteroplasmy level can vary between
tissues, between cells and across the lifetime of an individual
[43,45,51–59]. Additionally, highly metabolic tissues that are most
severely affected by m.3243A>G such as the brain and cardiac tissue,
are not easily accessible in living patients and heteroplasmy measure-
ments in autopsy samples may be influenced by necrosis caused by the
disease process and so are not simple to interpret [56].
Post-mitotic tissues, such as skeletal muscle, tend to have higher and
more stable levels of mutant mtDNA than more easily accessed mitotic
tissues, such as blood, urinary epithelial cells and buccal mucosa
[37,43,53,58,60–62]. Levels of m.3243A>G in blood fall by an esti-
mated 1.4-2.3% per year and several methods designed to adjust blood
heteroplasmy for this age-related decline have been devised [37,60,63].
Further studies are required to understand the molecular mechanism of
this negative selection. Its association with mitotic cell division
indicates a process involving either a replicative disadvantage and/or a
shorter life-span for stem cells carrying higher heteroplasmy levels; si-
mulation studies support this hypothesis [63,64]. Intra-cellular selec-
tion against sub-optimal mitochondria may also contribute, but would
not explain why selection does not seem to occur in post-mitotic cells.
Despite the presence of some inter-individual variation in the de-
cline of m.3243A>G heteroplasmy in blood, recent work has shown
that age-adjusted blood heteroplasmy is more highly correlated with
disease burden than urinary heteroplasmy level, possibly because the
latter shows much more variability within an individual. Age-adjusted
blood heteroplasmy is as good a predictor as muscle heteroplasmy,
although still only explains ~25% of the variability in disease burden
when combined with age [37]. Individuals with similar heteroplasmy
levels can present with different symptoms and some individuals with
high heteroplasmy levels are relatively asymptomatic [37,38]. Ad-
ditionally, the severity of some phenotypes, such as hearing impair-
ment, diabetes, ataxia and stroke-like episodes, seem to be more in-
fluenced by high heteroplasmy than others, such as gastro-intestinal
disturbance, migraine and psychiatric involvement [65], which are
common comorbidities of chronic diseases in general. However, mea-
sures of age and heteroplasmy cannot be used to predict key clinical
outcomes; factors other than heteroplasmy influence disease outcome
in m.3243A>G carriers and may well be tissue-specific.
Heteroplasmy levels may change rapidly between generations in a
phenomenon known as a mitochondrial genetic bottleneck [64,66,67].
This theory argues that only a small proportion of the total number of
mitochondrial DNA molecules are transmitted to offspring from their
mother. The bottleneck effect can result in mature oocytes containing
different levels of heteroplasmy. The varying severity of clinical phe-
notypes among family members with m.3243A>G could in part be
explained by this difference in the levels of transmitted mutation,
however the precise mechanism of this bottleneck is yet to be defined in
humans.
6. Mitochondrial DNA copy number
As well as different heteroplasmy levels, the absolute number of
mitochondria and mitochondrial genomes can vary between cells, tis-
sues and individuals. It is conceivable that the absolute wild-type
mtDNA copy number is important and that higher levels could com-
pensate for the presence of mutated mtDNA [37]. In support of this
theory, a positive correlation between oxygen consumption and mtDNA
copy number has been shown in m.3243A>G cybrid cells [68]. At a
population level, this does not seem to be the case in less metabolically
active tissues such as blood and urine, although the literature does
report some conflicting results [65,69,70]. In contrast, a low skeletal
muscle mtDNA copy number is associated with more severe disease.
This, combined with heteroplasmy and age, increases the proportion of
explained variation in disease burden to ~40% [37]. Although mtDNA
copy number may simply be a marker of a patient’s level of physical
activity, it is possible that cells from different individuals vary in their
ability to compensate for the presence of the m.3243A>G variation
and that this may influence clinical outcome [37,65,71,72].
7. Nuclear genetic modifiers
The nuclear genome encodes the majority of proteins involved in
OXPHOS; their production requires the coordinated expression of nu-
clear and mitochondrial genes [10,73]. In fact, ~1100 nuclear-encoded
proteins are believed to localize to the mitochondrion, reflecting its
numerous and varied roles within the cell [74,75]. It is hypothesized
that mito-nuclear cross-talk is controlled through anterograde signaling
from the nucleus, however, there is some evidence to suggest that mi-
tochondria can exert partial control over the nuclear genome, directly
modifying nuclear gene expression via retrograde signaling [49,76–80].
Genetic variation may determine the way that a cell adapts to the
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presence of m.3243A>G; potentially modifying metabolic pathways,
mtDNA copy number and heteroplasmy. Heritable factors could also
influence tissue-specific disease expression; distinct organ-specific
clinical features tend to cluster in families and monozygotic twins dis-
play remarkably similar clinical phenotypes, age of phenotypic onset
and tissue segregation of m.3243A>G heteroplasmy [59,81]. There-
fore, genetic variation could account for differences in clinical pre-
sentation, such as the presence of diabetes, as well as the overall se-
verity of disease.
More recently, the role of additive genetic factors in determining
specific clinical phenotypes associated with m.3243A>G has been
estimated across a cohort of 238 adults; psychiatric involvement,
hearing impairment, ataxia, migraine and cognition display moderate
to high heritability, with a larger proportion of phenotypic variance
being attributable to additive genetic factors than to heteroplasmy, age
and sex [65]. Interestingly, the transmission of m.3243A>G from
mother to child also has a moderate heritability, implying that nuclear
factors may interact with mitochondrial variants to modulate the ge-
netic bottleneck that occurs during oogenesis [65,82,83].
It is therefore possible that the nuclear background of an individual
has a greater influence on phenotypic expression than the established
clinical risk factors. Moderate to high heritability values imply a strong
overall genotype-phenotype correlation, but heritability does not pro-
vide any information about the genetic architecture (including the
number of genetic factors involved and the relative effect sizes of each)
[84]. The first step in identifying these factors is the assembly of large,
well-phenotyped patient cohorts that can be used in genetic linkage and
association studies [85]. Results from these studies should give us the
first clues as to whether phenotypes are influenced by one or two genes
with strong effects or genes acting in a polygenic fashion. Candidate
nuclear genes for overall disease severity will include those with a role
in oxidative phosphorylation and mtDNA replication and translation,
including those previously associated with Mendelian mitochondrial
diseases. For some phenotypes, such as m.3243A>G-related diabetes,
causative variation may be within genes previously associated with
monogenic or polygenic forms of the phenotype. In the case of diabetes,
this could be genes encoding proteins within the insulin pathway or
those involved in glucose sensoring, such as glucokinase [86]. Identi-
fying these nuclear factors will be challenging, but their characteriza-
tion will give us further insight into the molecular mechanisms driving
the phenotypic variability of m.3243A>G-related disease.
8. Other potential modifiers of mitochondrial disease
development
In addition to the elements previously discussed, there are other
factors known to influence the function of mitochondria. It is estab-
lished that mtDNA mutations accumulate with age due to the additive
effect of ROS damage in the mitochondrion, leading ultimately to the
dysfunction of mitochondria [87]. The relationship between dysfunc-
tional mitochondria and aging is not under the scope of this review, but
has previously been covered in depth [87–89]. It is important to note
that m.3243A>G-related disease is progressive [37,65,90], and a
number of disease phenotypes are affected by age; the severity of dia-
betes, hearing impairment, cerebellar ataxia and neuropathy have all
been strongly associated with increasing age [65]. Scoring of disease
using the Newcastle Mitochondrial Disease Adult Scale has demon-
strated that disease score increases with age, reaffirming the clinical
observations of progressive disease [37,65,90].
Biological sex has also been proposed to alter the risk of mi-
tochondrial disease development in patients; LHON is a mitochondrial
DNA disorder where only 50% of males and 10% of females who carry a
pathogenic mutation develop disease [91]; the protective effect of es-
trogens has been proposed to in part explain this sex bias [92]. In
m.3243A>G-related disease, stroke-like episodes have been reported
to occur more frequently in males than in females [45], but when
assessed in a different cohort of patients, this did not reach statistical
significance [65].
A number of environmental exposures have been proposed as
modifiers of disease progression in other pathogenic mitochondrial
mutations. In LHON, smoking [93–95], excess alcohol consumption
[94,96,97], and carbon monoxide poisoning [98], have all been re-
ported to affect the course of disease. Exposure to antiretroviral therapy
[99] has been suggested as a factor in the development of LHON and
phenotypes of other mitochondrial pathogenic mutations have been
suggested to be influenced by treatment with aminoglycosides [100]. In
rare mutations of mitochondrial polymerase γ (POLG), treatment of
individuals with valproic acid has been demonstrated to increase the
risk of liver toxicity [101]. Whether these risk factors can be translated
to m.3243A>G-related disease risk has not yet been confirmed.
The combination and the way in which these factors influence
m.3243A>G-related disease is still not fully understood. Historically,
retrospective studies have been used to disentangle the effects of mul-
tiple disease-influencing factors, but logistical problems and recall
biases make it difficult for these studies to be considered reliable when
employed for the investigation of rare disease [91].
9. Clinical approach to common phenotypes
It is evident that the interplay of all the factors highlighted in the
aforementioned sections, including heteroplasmy levels of the
m.3243A>G variant and differential tissue segregation, warrants an
approach that focuses on precision medicine for these patients.
Clinicians need to account for not only these genetic factors but also
environmental and lifestyle elements to provide accurate diagnosis,
appropriate assessment, health surveillance, counselling and effective
management for this complex condition. From the outset, the emphasis
of medical history-taking should be on bodily systems independently,
rather than on any particular syndrome. The complexities of phenotypic
expression prohibit a straightforward taxonomic approach of ascribing
specific genetic mutations to a particular mitochondrial clinical syn-
drome. The medical history may also provide information relevant to
heritable nuclear genetic factors. Carriers of the m.3243A>G variant
can present with single organ disease or several overlapping features,
making the diagnosis difficult for clinicians who do not encounter these
regularly in their practice.
The multitude of organ involvement with high-risk of disease pro-
gression means that these patients need access to specialist services
offering regular reviews with a multidisciplinary team that includes
specialists from neurology, endocrinology, cardiology, physiotherapy,
ophthalmology, obstetrics, clinical genetics and audiology. One model
of care is to deliver specialized services for these patients through a
small number of expert centers. This model is established in several
European countries and is gaining favor in the United States with the
recent designation of Mitochondrial Care Network with certified cen-
ters of excellence [102].
The use of validated clinical rating scales [46,103], the Newcastle
Mitochondrial Disease Adult Scale or the Newcastle Paediatric Mi-
tochondrial Disease Scale, can capture not only all the essential clinical
spectrum of mitochondrial disease but also provide a semi-quantitative
scoring of disease burden and a profile of disease progression, if used
serially over time. Another crucial aspect of the history-taking process
is family pedigree tracing. This is particularly pertinent to identify at-
risk individuals due to the maternal inheritance of m.3243A>G.
Clinicians should not only determine the presence of the m.3243A>G
variant in the pedigree, but also the levels of mutation because het-
eroplasmy levels among family members may vary.
From the diagnostic perspective, the m.3243A>G variant can be
sought non-invasively from either blood or urine samples. Given that
heteroplasmy levels may differ in different tissues, having at least two
samples in adult patients is helpful in prognostic counselling and in
planning the relevant health surveillance. Heteroplasmy measurements
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in a non-invasive-tissue such as blood are useful and provide a good
correlation with disease burden when adjusted for age, but in cases
where m.3243A>G is undetectable in blood, a second tissue such as
urine is also useful to test. Skeletal muscle biopsy has historically been
the ‘gold standard’ in the diagnostic work-up of mitochondrial disease
because this post-mitotic tissue is relatively easily accessible and con-
tains a large number of mitochondria for histochemical or enzyme ac-
tivity analysis. Another reason that skeletal muscle tissue has been
routinely used to study pathogenic mtDNA variants is that the levels of
mtDNA heteroplasmy appear to correlate with the histochemical
changes observed in the muscle fibers [104,105]. However, the in-
creasing use of molecular genetic tests has diminished the need for
these muscle biopsies, especially in common point mutations like
m.3243A>G [106]. Although NGS can be used for determination of
mtDNA heteroplasmy and deletions in mitochondrial diseases, pyr-
osequencing and long-range PCR are still commonly used for patients
who have a suspected m.3243A>G point mutation.
There is an increasing recognition of clinical manifestations of
m.3243A>G that are more common than the classical syndromes
[38,44,45,47,107,108]. In the next few sections, we will summarize
some of the common clinical manifestations.
9.1. Hearing impairment
Hearing impairment has been consistently the most prevalent fea-
ture reported in the literature, either as isolated manifestation or as part
of a disease spectrum, with the frequency ranging from 48% to 77%
[38,45,47,65,107,109–111]. The loss of hearing in carriers of
m.3243A>G is significantly faster than that of presbycusis, a hearing
disorder associated with ageing. Audiometry testing among carriers of
the m.3243A>G mutation, which is characterized by patonal curve
with downward sloping at high frequencies, has longitudinally de-
monstrated a loss of 2.9 dB per year for men and 1.5 dB per year for
women [112,113]. Several environmental factors have been suggested
as precipitants for the progression of hearing impairment [113–115],
but none of them have been credibly proven. Despite being identified in
population and patient cohort studies as the most prevalent feature of
m.3243A>G, the precise pathophysiological mechanism of hearing
loss caused by this particular point mutation has not been convincingly
elucidated. Some postulate that the degenerative effect of impaired
oxidative phosphorylation and of insufficient elimination of free radi-
cals on high-energy demand structures in the inner ear as possible ex-
planation but these hypotheses have not been tested [114,116,117].
Hearing levels for patients carrying the m.3243A>G mutation typi-
cally revealed with absent transient evoked otoacoustic emissions but
preserved auditory brainstem responses, indicating that the loss is co-
chlear in origin [118,119]. Hearing loss has a negative impact on
quality of life and it is often overlooked in patients. Therefore, clin-
icians should actively seek out hearing impairment in these patients,
not only because of how prevalent it is but also this mildly insidious
manifestation could be easily identified and corrected, albeit to a lesser
degree in severe cases, with the use of hearing aids or cochlear im-
plants.
9.2. Diabetes mellitus
Alongside hearing impairment, diabetes mellitus has been studied
extensively, in part because of the prevalence of the m.3243A>G
mutation within the population and its strong association with mater-
nally inherited deafness and diabetes (MIDD) syndrome [1,2,120].
Diabetes is also common in its own right with a prevalence of 5% in the
UK population. Epidemiological studies reported the frequency of the
m.3243A>G mutation in unselected groups of diabetic patients
ranged from 0% to 2.8% [120–123]. Given this relative scarcity of
mitochondrial diabetes, in busy general diabetic clinics it can be chal-
lenging even for the most astute clinicians to consider the m.3243A>G
mutation in a patient presenting with diabetes mellitus as an isolated
finding. However, atypical features for the general diabetes mellitus
population, such as maternal inheritance pattern, short stature or pre-
senile sensorineural hearing loss is likely to raise the clinical suspicion
of mitochondrial disease. Another distinguishing observation from ty-
pical Type 2 diabetes mellitus is the tendency for these mitochondrial
diabetic patients to have lower than average BMI [123,124]. Lower BMI
in these patients paradoxically correlates with earlier onset of diabetes,
earlier insulin requirements and higher HbA1c measurements [124].
The age of onset can be variable but typically develops in midlife with a
median age of onset of 38 years [123,124]. Mitochondrial diabetes
might develop insidiously with the gradual loss of metabolically-active
pancreatic B-cells but usually transitions rapidly to insulin dependence
within 2 to 4.2 years of initial diagnosis [123–125]. The risk of devel-
oping microvascular end-organ damage from the progression of
m.3243A>G-related mitochondrial diabetes in the forms of peripheral
neuropathy and end-stage renal disease are higher than the average
Type 1 or Type 2 diabetes mellitus. Despite the rapid progression, most
patients initially present with non-insulin dependent diabetes. The
agent of choice in the management of these patients is sulphonylurea
[120]. The risk of sulphonylurea-induced hypoglycaemia in some pa-
tients can be minimized by opting for shorter half-life preparation and
by titrating slowly from the lowest dose. Another first-line agent in the
general diabetic population is metformin. Although metformin has been
generally avoided in patients of m.3243A>G due to the potential risk
of exacerbating lactic acidosis, clinical problems are rarely observed.
9.3. Myopathy
Muscle symptoms of m.3243A>G mutation, including proximal
limb weakness, exercise intolerance, extraocular muscle weakness,
eyelid ptosis, muscle fatigue and pain, are common. The reported fre-
quencies of myopathy in natural history studies and meta-analysis of
m.3243A>G carriers ranged from 25% to 60% [126,127,129]. The
muscle manifestations in these patients are mainly mild to moderate
proximal limb weakness, especially of pelvic muscles, which result in
waddling gait and modified Gower’s sign [109,126,129,130]. The in-
creasing use of molecular genetic tests has diminished the need for the
previous ‘gold standard’ muscle biopsy for diagnosis of mitochondrial
disease, especially in common point mutations such as m.3243A>G
[106]. The presence of cytochrome c oxidase (COX)-negative fibers,
red-ragged fibers (RRF) and succinate dehydrogenase (SDH) staining
has long been the defining feature of mitochondrial dysfunction in the
muscle but may be absent in m.3243A>G patients. The risk of de-
veloping significant muscle symptoms in association with the
m.3243A>G variant increase with age. The myopathic symptom se-
verity has been shown to correlate with the biochemical hallmark of
mitochondrial dysfunction, namely the number of COX-deficient fibers
and subsarcolemmal aggregates detectable in muscle [126,130,131].
There is currently no convincing evidence for an effective treatment for
mitochondrial myopathy but the increasing number of ongoing clinical
trials currently provides optimism for potential disease-modifying
compounds in the coming years.
9.4. Cardiac disease
Apart from skeletal muscle, the myocardium is another tissue that
has a high aerobic metabolic demand and is often affected in patients
with mitochondrial disease. Cardiac muscle involvement, frequently
manifesting as hypertrophic cardiomyopathy, may occur in 20% to 40%
of patients with m.3243A>G-related mitochondrial disease [132] and
has been shown to lead to premature death [133]. Although left ven-
tricular hypertrophy is the most dominant cardiac abnormality
[134,135], more subtle cardiomyopathic changes and cardiac bio-en-
ergetic abnormalities, have been found in asymptomatic patients with
normal cardiac screening [132,133,136]. Cardiomyopathy is an
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independent predictor of both mortality and morbidity in these patients
[132,137,138]. In addition to the involvement of cardiac muscle,
rhythm abnormalities have also been reported frequently in patients
with m.3243A>G including Wolff–Parkinson–White syndrome, su-
praventricular tachycardia, atrial fibrillation, and depolarization ab-
normalities [134,139,140]. In some cardiac arrhythmias, the cardiac
fiber disarray could be the underlying pathology to ventricular ta-
chyarrhythmias in some forms of hypertrophic cardiomyopathy
[141,142]. Clinical reports have suggested there is a higher risk of
sudden and unexpected death in asymptomatic individuals harboring
the m.3243A>G mutation; thus, all carriers should have a cardio-
vascular risk assessment and surveillance should be according to clin-
ical recommended guidelines [138].
9.5. Stroke-like episodes
Since the acronym MELAS was first coined, stroke-like episodes
have been synonymous with m.3243A>G mitochondrial disease. The
term “stroke-like” for this focal cerebral metabolic crisis is clinically
misleading as the process bears very little resemblance to the strokes of
artherosclerotic or thrombo-embolic etiology. The stroke-like episode
in mitochondrial disease is characterized by acute or sub-acute meta-
bolic neurological dysfunction and, in contrast to vascular stroke, a
typical onset before the fourth decade (although older onset cases have
been reported) [143–145]. The prodromal features such as gradual
evolution of headache and prominent visual disturbance can develop
days or weeks before the onset of focal neurological deficit or motor
seizure. These visual symptoms, have been described as migrainous
visual aura by patients presenting for the first time, but in fact these
phenomena indicate the onset of occipital epileptic seizure [146]. The
severity of neurological sequelae of this cerebral metabolic crisis de-
pends on the extent of parietal, temporal and occipital lobe involve-
ment such as encephalopathy, dysphasia, dyspraxia, hemianopia, cor-
tical blindness, mild hemiparesis and psychosis. Not all of these features
are uniformly present. Therefore, the variable clinical picture of these
“stroke-like” episode in terms of onset of symptoms, severity, fre-
quency, duration and recovery phase can present challenges to clin-
icians managing patients presenting for the very first time without a
mitochondrial genetic diagnosis.
An important finding on cranial neuroimaging that helps distinguish
stroke-like episodes from arterial ischemic infarcts is the extension of
lesions beyond anatomical vascular territories. Although these meta-
bolic lesions have a predilection for the temporal and occipital lobes,
bilateral and asymmetrical changes are not infrequent as these existing
lesions evolve and predispose to further seizures [147,148]. Even if
there may be no clear lesion on neuroimaging, seizures are frequently
detected by electroencephalography in patients who have had a ‘stroke-
like’ episode [149]. The underlying pathophysiological process asso-
ciated with these ‘metabolic’ seizures has been proposed to be initiated
by interneuron mitochondrial respiratory chain deficiency, which
consequently alters the balance of excitation and inhibition in neural
networks, promoting neuronal hyperexcitability [150]. The dramatic
downregulation of OXPHOS subunits of complexes I and IV within the
GABA-ergic interneurons of these patients makes these interneurons
particularly vulnerable to the propagation of neuronal hyperexcitability
[151]. This acute process leads to rapid neuronal damage that has been
demonstrated by histopathological findings of micro-vacuolation, neu-
ronal cell dropout, eosinophilia, astrogliosis and secondary myelin loss
in patients with m.3243A>G [106]. While stroke-like episodes in-
itially result in discreet focal neurological deficits of the hindbrain,
repeated episodes impact interictal cognitive (frontal lobe) function
with patients demonstrating a persistent encephalopathy and radi-
ological evidence of brain atrophy. Psychiatric disturbance in the form
of depression (rather than psychosis) is also a frequent sequel of stroke-
like episodes and appears to be generally more common in mitochon-
drial disease patients. There are currently no established treatments
with proven efficacy in stroke-like episodes of mitochondrial origin.
The existing clinical drug studies to explore definitive disease-mod-
ifying treatment have been limited by small sample size and the lack of
natural history data. The difficulty in defining what constitutes a stroke-
like episode and the tendency for variable degrees of spontaneous re-
covery means that the true effect of acute therapies is difficult to prove
without large clinical randomized placebo-controlled trials.
9.6. Gastrointestinal features
Gastrointestinal symptoms due to gut dysmotility are also prevalent
in the m.3243A>G patients with up to more than three quarters of
carriers reporting gastrointestinal disturbance in large case-series [65].
These gastrointestinal disturbances include hard stools, flatulence and
bloating [152]. The underlying pathology behind gut dysmotility in
m.3243A>G patients is postulated to be a visceral myopathy, given
COX-deficient smooth muscle cells harbor very high levels of
m.3243A>G mutant load [153]. Pseudo-obstruction, a potentially
fatal complication of bowel dysmotility, is more common in patients
with high disease burden and multi-organ involvement and may occur
concomitantly with, or as a heralding symptom of, a stroke-like episode
[154] [155]. In busy acute general medical settings, pseudo-obstruction
is an important but challenging condition to recognize. A misdiagnosis
that leads to surgical intervention might increase the risk of dete-
rioration in these vulnerable patients with high disease burden. Prompt
recognition and expert medical gastroenterology input is key to avoid
unnecessary surgical interventions. The risk of pseudo-obstruction can
be mitigated with early detection during routine clinic surveillance for
symptoms of dysphagia, constipation, abdominal pain and distention,
as well as the timely management of malnutrition which is linked with
the severity of gastrointestinal symptom severity [152,154,156].
The m.3243A>G mutation also has a negative impact on linear
growth and weight gain; patients with more severe disease tend to be
shorter with a lower BMI [157]. Our clinical observation suggests that
those with early disease onset tend not to achieve their expected adult
height. Low final adult height has been shown to be an indicator of
disease severity and rate of disease progression [157]; thus, height and
weight measurements in clinical settings are helpful for prognostication
and counselling. Although m.3243A>G heteroplasmy level is nega-
tively associated with BMI and height, the correlation is not strong;
there can be marked disparities in growth and BMI between two in-
dividuals with precisely the same blood and muscle heteroplasmy,
again indicating nuclear modifiers of disease expression. Other common
associated symptoms with suboptimal growth are early satiety and gut
dys-motility [153,158]. Our clinical experience suggests that even with
the use of percutaneous gastrostomy or nasogastric tube feeding it is
still very challenging to achieve satisfactory improvement in linear
growth or BMI in these individuals. Nonetheless, supplementary
feeding that supports good nutritional status and avoidance of further
weight loss are simple measures that may improve long-term survival.
10. Prevention of transmission
The pathogenic variant m.3243A>G is maternally-inherited and so
male carriers will not transmit the variant to their children, while fe-
males are highly likely to transmit at least some of the m.3243A>G
variant to all of their offspring. However, the calculation of recurrence
risk for women who carry the m.3243A>G is not straightforward
given the unpredictable transmission, which is largely determined by
the size of the genetic bottleneck. This means that mature oocytes may
contain vastly different levels of m.3243A>G heteroplasmy, resulting
in a highly variable risk of transmission of disease and making genetic
counselling and reproductive options extremely challenging. At the
moment, there are essentially four options available for at-risk couples
– prenatal testing, preimplantation genetic diagnosis (PGD), oocyte
donation and mitochondrial donation [159]. The first two options are
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suitable for women who harbor low levels of heteroplasmy while
women with high levels may benefit from the latter two options [160]
Recently, maternal m.3243A>G heteroplasmy measurements were
used to calculate the risk of having a clinically affected child, which will
allow evaluation of women who will benefit from mitochondrial do-
nation [83].
11. Research in the era of precision and personalized medicine
There is a significant need to develop a deeper understanding of
m.3243A>G-related disease; the vast constellations of phenotypes
with which patients present is indicative that more precise definitions
of disease are needed. To this end, researchers must utilize multiple
sophisticated techniques to understand the variation observed on a
clinical/phenotypic level, and at the genetic/cellular level. Established
influences on phenotypic expression such as heteroplasmy, have al-
ready been discussed in this review, the challenge that now faces re-
searchers is the identification of novel influencing factors and how they
interact with established m.3243A>G-related disease modifiers.
The complexity of this disease is compounded by many factors, in-
cluding the inter-individual variation that is present within a disease
population. There can be a significant difference in presentation be-
tween the phenotypes of individuals, even when known influential
factors are relatively similar. It is essential that population level dif-
ferences are accounted for when approaching research of any complex
disease. Effective exploration and untangling of potential genetic or
environmental influences of disease requires a large cohort of patients
and, ideally, family data, including information regarding asympto-
matic carriers of the m.3243A>G variant. The correlation of pheno-
types and genotypes of disease will facilitate the identification of new
genotypes related to specific phenotypes of m.3243A>G-related dis-
ease and will make it possible to provide patients with a more precise
estimation of disease burden and progression.
Clearly illustrated by the unique aspects of mitochondrial genetics,
there are also variables that occur within the individual. For example,
tissue-specific segregation of mtDNA means that heteroplasmy is not
necessarily at a uniform level throughout the systems of the body.
Accounting for intra-individual variation is a challenge that must be
met in the field of complex disease research. Using a variety of long-
itudinally collected patient data is key to illuminating the presence of
inter-individual variation; collection of patient tissue biopsies enable
the elucidation of tissue specific effects, as well as calculation of het-
eroplasmy level, copy number and other factors which may have an
impact on clinical outcome and cellular biochemical phenotype. The
occurrence of inter-individual differences must also be addressed when
defining the mechanism of disease. Use of multiple genetic backgrounds
in cellular studies will go some way to making results more robust and
translational.
Longitudinal phenotypic studies, in combination with prospective
recruitment of individuals to well-defined cohorts of patients has led to
groups of mitochondrial patients who are ready to participate in clinical
trials. One possible route is the repurposing of already existing medi-
cations and treatments, which can significantly reduce the time it takes
to be approved for patient use. Currently, there are a wide range of
approaches being studied in Phase 1, 2 and 3 clinical trials in
m.3243A>G patients with mitochondrial myopathy, including the
targeting of 1) mitochondrial biogenesis (Bezafibrate, Nrf2 activator,
Acipimox, Nicotinamide riboside); 2) oxidative phosphorylation
(Coenzyme Q10, idebenone, riboflavin, thiamine); reactive oxygen
species (KH176, idebenone); 3) increasing NAD+ (acipimox, nicoti-
namide riboside) and 4) cardiolipin stabilization (elamipretide)
[161–164]. It is important that clinical trial cohorts are as homogenous
as possible, not just those with a relevant mitochondrial mutation, but
also with phenotypes that are relevant to drug targets.
12. Conclusion
The extensive phenotypic variability associated with this mi-
tochondrial DNA variant and the unique characteristics of mitochon-
drial genetics, which include maternal inheritance and the multicopy
nature of the mitochondrial genome, require us to treat m.3243A>G-
related disease as a truly complex disorder, both in the research la-
boratory and the clinic. Investigating it as such, through the colla-
borative efforts of clinicians and researchers, will continue to empower
the creation of clinical and diagnostic tools to aid with disease diag-
nosis, prognosis, and the prediction of an individual’s response to
treatment, as seen in fields such as cancer research. In turn, this will
allow the development of more precise therapeutic strategies and in-
terventions that can be applied on a patient-by-patient basis, and fa-
cilitate the bespoke tailoring of clinical care. The landscape of clinical
care for patients with m.3243A>G has evolved, with increasing re-
cognition of the range of phenotypes that can result from this single
point mutation. To focus purely on the historical classification of syn-
dromes such MELAS or MIDD is a blinkered approach to the modern
day medicine for these complex patients. Advances in mitochondrial
genetic sequencing have aided the diagnosis of patients without typical
disease patterns or syndromes, and also allow heteroplasmy level to be
assessed. Once a molecular diagnosis is made, input from several spe-
cialties is crucial in providing comprehensive and individualized care
for these patients. There is currently no cure for m.3243A>G mi-
tochondrial disease but reproductive techniques, such as mitochondrial
donation, offer hope for these individuals who wish to prevent the
transmission of this disorder to their offspring. As the present pursuit
for disease-modifying drugs for m.3243A>G through clinical trials
intensifies, it will be an exciting time for the clinical practice of mi-
tochondrial medicine in the coming years.
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